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Abstract
OBJECTIVE—Inflammatory markers such as C-reactive protein (CRP) are related to obesity in
adults, but the association is less clear in children. Our objective was to examine relationships
between multiple markers of inflammation and children’s weight status; we hypothesized that the
prevalence of inflammatory markers would increase as weight status increased.
METHODS—We conducted a cross-sectional analysis of children in the United States aged 1 to
17 years in the National Health and Nutrition Examination Survey, 1999–2006. Children were
categorized using weight-for-length when age < 2 years and BMI for ≥2 years, as very obese
(≥99th percentile), obese (< 99th and ≥95th percentile), overweight (< 95th and ≥85th percentile),
and healthy weight (> 5th to ≤85 thpercentile)according to expert consensus. Our main outcome
measures were high-sensitivity CRP and absolute neutrophil count, in addition to a novel third
measure: ferritin controlled for iron status using a ferritin/transferrin ratio. We used Cox
proportional hazards models to examine risk of abnormal values of inflammatory markers
according to weight.
RESULTS—Increased risk of a CRP level of > 1.0 mg/L was evident among very obese children
from ages 3 to 5 years (hazard ratio [HR]: 2.29; P < .01) through 15 to 17 years (HR: 4.73; P < .
01). Increased risk of abnormal neutrophil count among very obese children began at 6 to 8 years
(HR: 2.00; P = .049), and increased prevalence of abnormal ferritin/transferrin ratio began at 9 to
11 years (HR: 7.06; P < .001).
CONCLUSIONS—Multiple inflammatory markers are strongly and positively associated with
increasing weight status in children, and this relationship starts as young as age 3. Elevated
inflammatory markers in very young obese children are particularly concerning, because
inflammation may cause long-term, cumulative vascular damage. This deserves additional
research via longitudinal design.
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WHAT’S KNOWN ON THIS SUBJECT
Inflammation, a risk factor for cardiovascular morbidity, is associated with obesity in
adults. Small clinical samples and older nationally representative data have revealed
correlations between CRP and BMI percentiles in school-aged children and adolescents.
WHAT THIS STUDY ADDS
Using recent nationally representative data from children aged 1 to 17 and multiple
markers, the relationship between inflammation and obesity begins at age 3. This study
also provides prevalence of abnormal inflammatory markers in current, clinically
relevant BMI subcategories.
Obesity in childhood increases the risk of obesity in adulthood, and obesity in adulthood is
associated with cardiovascular disease.1 Although the mechanisms are likely complex, a
possible link between these 2 conditions is chronic, low-grade inflammation. Population-
based studies have shown a clear relationship between obesity and high-sensitivity C-
reactive protein (CRP) levels,2 and others have demonstrated a cause-and-effect relationship
between adiposity and inflammation, with changes in weight resulting in directional changes
in CRP.3,4 Inflammation may change the risk for cardiovascular disease by its association
with traditional cardiovascular risk factors such as high-density lipoprotein, or inflammation
may have a direct effect on the endothelium, atherogenesis, or the stability of atherosclerotic
plaques.5,6 Multiple prospective studies in adults have shown CRP to be predictive of future
cardiovascular disease, independent of obesity.7–9
It is biologically plausible that increased length of exposure to an inflammatory state could
increase the risk of vascular damage and morbidity. If overweight or obese children have
low-grade inflammation, this inflammation could increase the risk of long-term vascular
damage and also indicate risk for future cardiovascular events. A few studies have
demonstrated a relationship between CRP and obesity in childhood but were limited by use
of small, clinic-based samples,10,11 consideration of only older children or adolescents,12 or
limited measures of inflammation.13 Using currently outdated definitions of obesity, Visser
et al14 examined inflammation in a nationally representative sample of older children, and
Ford et al15,16 examined CRP and BMI in children older than 3 years. It is important to note
that an increase in the prevalence of obesity, particularly among very young children,17
since the year 2000 when the most recent of these studies was conducted underscores the
need to examine updated, more comprehensive data about the presence of inflammation in
children.
A more in-depth and current understanding of the relationship between obesity and
inflammation throughout childhood requires the use of multiple waves of recent nationally
representative data to increase sample size and validity and analysis by narrow age
groupings to identify the age at which any association between obesity and inflammation
appears. Also, clinically relevant relationships require using current definitions of obesity
that are used in practice, including the increasingly common “severely obese” category
(BMI ≥ 99th percentile) with heightened risk of long-term health sequelae. Finally, the use
of multiple different inflammatory markers may elucidate whether obesity is largely
associated with elevations in CRP level or whether obesity is associated with a widespread
inflammatory process that involves multiple different branches of the inflammatory cascade.
To these ends, and to expand previous work, we analyzed the most recent multiple years of
data from the National Health and Nutrition Examination Survey (NHANES) to determine
the associations between 3 distinct markers of inflammation and increasing weight status in
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children in the United States with a specific goal of isolating effects according to age. We
hypothesized that inflammation and obesity would be highly associated throughout
childhood and that the association would begin earlier than previously described.
METHODS
We analyzed data from the NHANES, years 1999–2006. The NHANES is a stratified,
multistage probability sample of the civilian, noninstitutionalized population of the United
States. It includes computer-based interviews, an in-home questionnaire on a variety of
demographic and health topics, an examination that includes a thorough physical
examination, and laboratory measures.18
Outcome Variables
We examined 3 markers of inflammation: CRP, absolute neutrophil count (ANC), and
ferritin level controlled for iron status. The last measure has not been used previously but is
described and tested here as a biologically plausible measure of inflammation that could
have a relationship to obesity.
The NHANES measured CRP in all children aged 3 and older in 1999–2002 and all children
aged 1 and older in 2003–2006. CRP was quantified by using latex-enhanced nephelometry,
and a high-sensitivity assay was performed on a Behring (Deerfield, IL) nephelometer.19
The lower limit of detection for this test was 0.2 mg/L. For continuous analyses, all values
of < 0.2 mg/L were coded as equal to 0.1. Research in adults has indicated increased risk of
cardiovascular disease beginning at values of ≥1.0 mg/L,20 so we used this value as a cut
point for our analyses. However, because of a lack of evidence defining important cut points
for CRP in children, we also used a definition of elevated CRP of 4.0 mg/L, representing the
survey-weighted 95th percentile. There is insufficient data to suggest a cutoff related to
health outcomes in children; therefore, our use of the 95th percentile is intended only to
analyze weight-related trends. We excluded children with CRP levels of > 10.0 mg/L from
all analyses, because values that high likely indicate a separate, active inflammatory clinical
process.
Complete blood count was performed on all children aged 1 year and older, and we used the
component ANC as an inflammatory marker because of previous research that demonstrated
that it may be predictive of cardiovascular disease in adults.21 We considered neutrophils
elevated when the ANC was > 6.6 × 103 μL or when the percentage of white blood cells that
were neutrophils was > 67.2%, representing the survey-weighted 95th percentile of the final
analytic sample.
Iron studies were completed for all children 1 year and older in 1999–2002. In 2003–2006,
these studies were available only for children aged 3 to 5 years and girls aged 12 to 18 years.
Ferritin is increasingly recognized as not only a test for serum iron status but also an acute
phase reactant that is elevated in inflammatory conditions.22 However, there are no
established cutoff values for ferritin in children that represent low-grade inflammation. In
addition, interpretation of ferritin values depends on whole-body iron status including
transferrin saturation. Therefore, we introduce a ratio of ferritin to transferrin (F/T)
saturation as a ferritin-based inflammatory outcome with control for iron status. Because no
clinical cutoffs exist for this measure, we defined F/T saturation as high when the value was
greater then the weighted 95th percentile in our final analytic sample. Therefore, for
categorical analyses, F/T was considered elevated if it was > 4.81.
These 3 markers of inflammation were chosen because they are incited in part by exposure
to shared inflammatory factors, but also each has unique branches of the inflammatory
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cascade: CRP increases directly with interleukin 6 levels, the neutrophil count largely
depends on granulocyte colony-stimulating factor, and the ferritin level increases with
macrophage activation.23 Although F/T has not previously been validated as an
inflammatory marker that is related to future health outcomes, we included this measure of
inflammation controlled for iron status to establish the relationship of obesity and
inflammation across multiple inflammatory cascades and measures.
Independent Variables
We used height and weight as measured during the examination component to determine
age- and gender-specific weight-for-length for children younger than 2 and those aged 2 or
older to calculate BMI. SAS (SAS Institute, Inc, Cary, NC) code developed for the purpose
determined BMI percentiles.24 Children were then categorized using weight-for-length or
BMI percentiles and current Centers for Disease Control and Prevention and expert
committee recommendations as very obese (≥99th percentile), obese (< 99th and ≥95th
percentile), overweight (< 95th and ≥85th percentile), or healthy weight(< 85th percentile).
25 It should be noted that these definitions are based on BMI percentile and do not represent
the distribution of the sample or of the current population. Rather, they derive from BMI
distribution in the population from 1963 to 1994,26 and on the basis of current distributions,
> 5% of our study population will be above the 95th percentile. We excluded underweight
children (BMI < 5th percentile) because we were primarily interested in the relationship
between excess weight and inflammation, and because these children may be more likely to
have inflammation associated with other chronic illnesses. European growth charts, which
do include BMI for children from birth, demonstrate generally good agreement between
BMI and weight-for-length.27
To avoid confounding between inflammation related to chronic illness (particularly ferritin)
and inflammation associated with obesity, we excluded all children with anemia, which we
de-fined by using hemoglobin level (< 11.0g/dL for children aged 0–4 years, < 11.5g/dL for
children aged 5–12 years, and < 12.0g/dL for children aged 13 years and older)28 or parental
report of taking medication for iron-deficiency anemia. In addition, all girls who reported
using oral contraceptives were also excluded because of known relationships between
estrogen use and inflammation.29
We controlled for gender, race/ethnicity, current illness, age, and smoking exposure
(children with serum cotinine concentrations of ≥12 ng/mL were classified as exposed to
cigarette smoke either actively or passively30), the latter because of its known relationship
to inflammation.31 Race/ethnicity was categorized as white, black, Hispanic, or other.
Because of minimal differences noted in descriptive statistics, we chose to control for, rather
than stratify according to, race and gender. To control for current illness, we adjusted for 3
binary variables: having a “head cold” or “influenza or an ear infection” in the last 30 days
or having a diagnosis of asthma.
Statistical Methods
We began by examining the bivariate relationships between each inflammatory marker and
obesity. We examined mean differences in the outcome measures according to weight
category, testing with an adjusted Wald test. We also examined differences in prevalence of
abnormal values according to weight category, testing differences by using a Pearson χ2 test.
Consistent with recommendations, we did not adjust for multiple comparisons, because each
comparison has an independent null hypothesis determined before analysis.32
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Multivariate analyses used Cox proportional hazards models to develop hazard ratios (HRs)
of the effect of weight on abnormal outcomes. This model performs well and provides HRs
that are more clearly interpretable than odds ratios from logistic regression.33
All analyses were adjusted for the complex survey design of the NHANES and performed
by using the survey estimation routines in Stata 10.0 (Stata Corp, College Station, TX). The
study was deemed exempt from human subjects review by the University of North Carolina
public health/nursing institutional review board (07–1967) because it used only deidentified
secondary data.
RESULTS
After removal of children who were anemic (2.7%), taking oral contraceptives (< 1%), and
with CRP levels of > 10.0 mg/L, the final sample size was 16 335. Those excluded were
more likely to be black, possibly because of greater prevalence of anemia in black children,
and more likely to be female, because of the use of oral contraceptive use as an exclusion
criteria. The prevalence of potential confounders (Table 1) included cotinine levels
indicative of tobacco use or significant secondary exposure (3%), a “head cold” in the
previous 30 days (27%), having “flu or ear infection” in previous 30 days (7.2%), or an
asthma diagnosis (15%).
Correlations between CRP, ANC, neutrophil percent, and F/T were significant but weak,
ranging from r = 0.10 to 0.36 and confirming that each is, at least in part, acting
independently in its association with obesity. Table 2 presents percentile distributions of
each inflammatory marker. Median CRP was 0.3 mg/L (mean: 0.89 mg/L), median ANC
was 3.4 × 103 μL (mean: 3.67 × 103 μL), and median F/T was 1.38 (mean: 1.86). Only the
prevalence of elevated ANC (not CRP or F/T) differed according to gender. Some ethnicity-
and race-related differences in inflammatory markers were noted (Table 1).
The prevalence of a CRP level > 1.0 mg/L was significantly greater in very obese children
beginning at age 3 and continuing through adolescence (Table 3). In children aged 15 to 17
years, 83.3% of those who were very obese had a CRP level of > 1.0 mg/L, compared with
only 18.1% of healthy-weight children (P < .001). Similarly, a weight-related increase in
prevalence of elevated F/T and ANC began very early in life. However, the prevalence of
elevated F/T in the very obese was not significantly different from healthy-weight children
until the age of 6. Increased prevalence of abnormal ANC began at age 9.
The increased prevalence of abnormal inflammatory markers among obese children
remained when controlling for demographic and other potentially proinflammatory factors.
Increased risk of a CRP level of > 1.0 mg/L (Fig 1) was evident at 3 years of age among
very obese children(HR: 2.29 [95% confidence interval (CI): 1.52–3.44]), peaked among
children aged 9 to 14 years and continued through adolescence (HR: 4.73 [95% CI: 3.72–
6.02]; ages 15–17). HRs were generally larger with similar distribution for risk of CRP
levels of > 4.0 mg/L. Similar but somewhat smaller increases in risk were also seen for
abnormal ANC (Fig 2) beginning at age 6 and F/T beginning at age 9 (Fig 3).
DISCUSSION
To our knowledge, this is the first study to demonstrate a strong and consistent association
among inflammatory markers and obesity in a large, recent nationally representative sample
of US children across the full childhood age range. Although associations between
inflammatory markers and obesity were greatest for older children, this relationship was
observed among children as young as age 3 and was consistently demonstrated for 3
different measures of inflammation. Our analysis also provides national prevalence
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estimates of elevated inflammatory markers in children at varying weight statuses and age
groups.
In the present era of an obesity epidemic, when 14% of preschool-aged children (2–5 years)
are overweight,17 our study is an important addition to the literature. Previous research used
ultrasound techniques to show that increased CRP seems to be related to vascular intima
media thickness in children and early atherosclerotic changes related to inflammation.11,34
Taken together with these pathophysiologic findings in small clinic samples, the results of
our work raise concerns about the entire population of overweight children’s risk for long-
term cardiovascular disease. Ford et al analyzed NHANES 1999–2000 and demonstrated
associations between BMI percentile and increases in CRP.35 Since that study, the
definitions of overweight/obesity have changed, and the epidemic of obesity has progressed
within all age groups of the population. Our study, in which we used larger, more recent
nationally representative data with a broader age range and multiple inflammatory markers,
therefore extends earlier work by Ford et al and other authors.10–15,36
Our study results also demonstrated the persistence of the relationship between weight status
and inflammation despite using inflammatory markers based on different terminal
inflammatory pathways. The weak correlations between the measures suggest that each is
measuring a somewhat different process yet is independently and similarly associated with
weight status. Each inflammatory pathway may have different effects on health outcomes.
Future research will need to examine their usefulness, individually or combined, in
predicting future cardiovascular and other health outcomes.
Whereas our study has important strengths, there are also limitations. First, we were unable
to fully control for pubertal age, which may affect cardiovascular risk factors including
inflammation. NHANES no longer includes Tanner staging for measurement of puberty, and
there are also few other sexual development proxies available. However, our results are
similar for age groups in which there may be significant variation in puberty and for age
groups in which the great majority of children have likely begun puberty, strongly
suggesting that the lack of control for puberty had minimal impact on our analyses. Second,
given the cross-sectional design, we are unable to determine the direction of association
between inflammation and obesity. Although there is evidence that adipose tissue acts as an
active endocrine organ that stimulates inflammatory cascades,5,6,37 it is possible that
inflammation could also incite obesity. More importantly, although the relationship between
inflammation and adiposity is evident in very young children, the cross-sectional design
does not permit us to comment on whether the relationship is maintained for individual
children across time or certainly into adulthood. Third, because inflammatory markers do
vary somewhat according to age, our use of the same cutoff for all ages may obscure subtle
relationships. However, using age-specific 95th percentile as cutoffs for abnormal values did
not significantly change the results. Finally, we used 2 less-established markers of chronic
inflammation, in addition to the more accepted and conventional marker, CRP. Whereas the
F/T marker (described here for the first time) may ultimately be a novel way to examine
ferritin while controlling for iron status, there are currently no descriptions of its distribution
in the population, and its use here is based on face validity alone.
Why we did not identify a relationship between elevated inflammatory markers and obesity
in infants and children younger than 3 years of age is unclear, although very obese 1- to 2-
year-olds did have a trend toward elevated inflammatory markers. It is possible that
inflammatory markers are not elevated immediately with obese status, and therefore obese
children in the youngest age range would not yet have elevated markers. Longitudinal study
would better test this hypothesis. Possibly, the weight-for-length percentile used for the
youngest children altered the relationship between weight status (otherwise assessed via
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BMI) and inflammatory markers. Because the number of 1- to 2-year-old children in our
sample was smaller, it is possible that a more balanced sample distribution would have
conferred statistically significant differences at all ages.
It is also unclear why the association between obesity and inflammatory markers seems to
peak at ages 9 to 11. One possibility is that the lack of pubertal controls disguises a more
complex relationship between adiposity changes in the early pubertal period and
inflammation perhaps related to insulin resistance.38 In addition to specific puberty-based
differences, there may be biological or physiologic differences in this developmental period
that we are unable to elucidate using our data.
Our research brings to the forefront many important questions. First, with so many children
potentially at risk for health-related sequelae from obesity, does the presence of increased
inflammatory markers predict those who will fare poorest? Future research needs to focus on
the ability to use inflammatory markers to predict cardiovascular risk in children, as has
been done in adults. In this way, inflammatory markers could be used as a second layer of
screening to determine who would most benefit from obesity interventions. Although
cardiovascular screening of adults by using CRP is debated,39 it is clear that there is a
relationship between CRP level and future cardiovascular morbidity.40,41 In addition, there
is evidence that treating older adults with an elevated CRP but normal lipid levels using 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduces mortality.42 To
be enrolled in the 3-hydroxy-3-methylglutaryl coenzyme A reductase treatment trial
(JUPITER trial), subjects had to have a CRP level of > 2 mg/L,42 which makes it
concerning that a significant proportion of obese children have CRP levels of > 4 mg/L.
Although current recommendations and debate about statin use in children focus on the
reduction of hyperlipidemia, the JUPITER trial may stimulate researchers to investigate the
benefits of statin usage in children beyond cholesterol reduction alone.
Another question is whether biomarkers could change quickly with lifestyle change and
thereby be useful to motivate and support patients early in the course of improved lifestyles.
Because there is evidence that physical activity, specific dietary behaviors, and other
environmental factors play a role in the inflammatory process,37,43 could counseling that
focuses on improved diet and activity improve inflammation even before weight decreases?
CONCLUSIONS
Obese children in this nationally representative sample already had measurably elevated
markers of inflammation. Additional research should determine whether inflammation
incites a cascade that over many years leads to cardiovascular damage and subsequent
cardiovascular events and whether earlier exposure to inflammation causes cumulative
damage. If such processes were confirmed, inflammation may transform the current
epidemic of childhood obesity into a future epidemic of cardiovascular morbidity and
mortality in adults, further justifying early obesity prevention efforts.
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Relative risk of a CRP of > 1.0 mg/L, compared with healthy-weight children. a P < .01.
(Tabular data are available in Table 4.)
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Relative risk of an ANC of > 6600, compared with healthy-weight children. a P < .05.
(Tabular data are available in Table 4.)
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Relative risk of an F/T of > 4.81, compared with healthy-weight children. a P < .05.
(Tabular data are available in Table 4.)
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TABLE 2
Distribution of Inflammatory Markers
Percentile CRP, mg/L ANC, × 103 μL Ferritin
1st 0.10 1.10 0.26
5th 0.10 1.60 0.44
10th 0.10 2.00 0.58
25th 0.10 2.60 0.87
50th 0.30 3.40 1.38
75th 0.90 4.50 2.20
95th 4.00 6.60 4.81
99th 7.60 8.90 8.00
Mean 0.89 3.67 1.86
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